Robert Golder, MD
Nephrology · Kansas City, MONPI 1669461513
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 284 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,212, 2.0 times the $595 reported in 2019.
Across 284 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$879
- Amgen$487
- Calliditas Therapeutics US Inc.$399
- Vifor Pharma, Inc.$355
- AstraZeneca$352
- Akebia Therapeutics Inc$316
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,97496%
- Education$2074%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 61 | $879 |
| Amgen(2 entities) | 31 | $487 |
| Calliditas Therapeutics US Inc. | 18 | $399 |
| Vifor Pharma, Inc. | 26 | $355 |
| AstraZeneca(2 entities) | 16 | $352 |
| Akebia Therapeutics Inc | 18 | $316 |
| ANI Pharmaceuticals, Inc. | 13 | $281 |
| Mallinckrodt Hospital Products Inc. | 9 | $255 |
| Otsuka America Pharmaceutical, Inc. | 12 | $224 |
| Bayer | 11 | $201 |
| Medtronic | 10 | $184 |
| Novartis | 7 | $184 |
| Fresenius USA Marketing, Inc. | 9 | $164 |
| OPKO Pharmaceuticals, LLC | 9 | $139 |
| Nxstage Medical, Inc. | 2 | $132 |
| Novo Nordisk | 7 | $130 |
| GSK | 5 | $96 |
| Mozarc Medical US LLC | 4 | $83 |
| Boehringer Ingelheim | 4 | $75 |
| Mallinckrodt Enterprises LLC | 3 | $69 |
| Shield Therapeutics Inc | 1 | $35 |
| Aurinia Pharma U.S., Inc. | 2 | $34 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
| Apellis Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Filspari$133
- NXSTAGE CARTRIDGE EXPRESS$113
- NXSTAGE PUREFLOW SOLUTION$113
How this compares
$5,181 in reported general payments places this provider in the 80th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 37 | $83,978 |
| JardianceEmpagliflozin | 35 | $34,524 |
| Sevelamer Carbonate | 142 | $30,110 |
| FarxigaDapagliflozin Propanediol | 23 | $25,275 |
| EliquisApixaban | 22 | $17,543 |
| AuryxiaFerric Citrate | 14 | $17,018 |
| JanuviaSitagliptin Phosphate | 12 | $6,252 |
| Lanthanum Carbonate | 15 | $4,533 |
| Nifedipine ErNifedipine | 139 | $4,435 |
| Calcium Acetate | 40 | $2,293 |
| Potassium Chloride | 69 | $1,330 |
| Midodrine Hcl | 19 | $956 |
| Losartan Potassium | 140 | $815 |
| Hydralazine Hcl | 89 | $770 |
| Carvedilol | 101 | $672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $164 | $83,97837 claims |
| Boehringer IngelheimJardiance | $75 | $34,52435 claims |
| AstraZenecaFarxiga | $352 | $25,27523 claims |
| Akebia Therapeutics IncAuryxia | $316 | $17,01814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 253 nephrology providers in Missouri.
Other nephrology in Kansas City
- Ahmed AwadKansas City$79K
- Richard CaplingKansas City$31K
- Tarek DarwishKansas City$8K
- Jignesh ShahKansas City$7K
- Adnan KhanKansas City$7K
- Archana GoelKansas City$5K
- Ryan LustigKansas City$4K
- Pranavkumar DalalKansas City$4K
- Rafael TorosyanKansas City$3K
- Derek LarsonCreve Coeur$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.